secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inspire Medical Systems, Inc. (INSP)
CIK:        0001609550
Form:       8-K
Filed at:   2022-08-02T23:59:59+00:00
Accession:  0001609550-22-000039
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inspire Medical Q2 revenue $91.4M (+73%), net loss $14.5M; FY guidance raised to $354M-$362M
--------------------------------------------------------------------------------

- Q2 revenue $91.4M (+73% YoY); U.S. $87.9M (+78%), ex-U.S. $3.5M (-3% due to FX).
- GAAP net loss $14.5M ($0.53 diluted EPS) vs $13.1M ($0.48) prior year; gross margin 84.5% (down from 85.8%).
- FY2022 revenue guidance raised to $354M-$362M (from $336M-$344M); gross margin guidance lowered to 83%-85%.
- Activated 52 new U.S. centers in Q2 (total 785); added 17 U.S. sales territories (total 191).
- Received FDA approval for expanded full-body MRI; Breakthrough Device Designation for expanded AHI/BMI indication.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1609550/000160955022000039/0001609550-22-000039-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1609550/000160955022000039/insp-20220802.htm
  HTML page:      https://secwatch.observer/filing/0001609550-22-000039

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer